<DOC>
	<DOC>NCT01268878</DOC>
	<brief_summary>The ending of this study is to describe the effect of febrile neutropenia on patients who receive a chemotherapy by docetaxel+cisplatin+fluorouracil(TPF).</brief_summary>
	<brief_title>Hematologic Toxicity Observation of the Docetaxel+ Cisplatin+ Fluorouracil (TPF)Medical Protocol</brief_title>
	<detailed_description>In this study we will describe - habits of medical staff in prescription of growth factors or antibiotic prophylaxis - ratio of patients treated by growth factors in primary or secondary prophylaxis - ratio of patients treated in primary prophylaxis who present a febrile neutropenia - ratio of patients who need to be hospitalized and the duration of those hospitalizations. - causes of lateness, of decreasing, and of stop of chemotherapy - antibiotic and growth factors prophylaxis tolerance .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>patients with histologically proved head and neck squamous cell carcinoma age: more than 18 patients who are beginning a chemotherapy (docetaxel+cisplatin+ 5FU) patients must have been informed of automatic data processing concerning them. previous chemotherapy for the head and neck squamous cell carcinoma previous chemotherapy for an other cancer in the two years before intercurrent illness that could significantly interfere with chemotherapy such as HIV infection, infection or active febrile illness, a chronic intestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>effect of febrile neutropenia resulting chemotherapy by TPF</keyword>
</DOC>